

IBS-D: What to Do When Typical Treatment Methods Fail

Darren M. Brenner, MD, AGAF

REFERENCES

Facts About IBS: Statistics. International Foundation for Functional Gastrointestinal Disorders website. <https://www.aboutibs.org/facts-about-ibs/statistics.html>. Accessed August 8, 2018.

Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. *Gut*. 2015;64(1):84-92. <https://www.ncbi.nlm.nih.gov/pubmed/24727487>

Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? *Therap Adv Gastroenterol*. 2012;5(4):261-268. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388522/>

Brenner DM, et al. Efficacy and safety of eluxadolone in IBS-D patients who report inadequate symptom control with prior loperamide use: a phase IV, multicenter, multinational, randomized, placebo-controlled, double-blinded study (RELIEF). Presented at the Annual Scientific Meeting of the ACG; October 5-10, 2018; Philadelphia, PA. [Abstract 344].

Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. *Dig Dis Sci*. 2016;61(2):560-571. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729798/>

Chey WD, et al. Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients with IBS-D: A Randomized, Controlled, Repeat Treatment Study. Presented at DDW, May 16-19, 2015; Washington, D.C. [Abstract No. 313].

Di Palma JA, Herrera JL. The role of effective clinician-patient communication in the management of irritable bowel syndrome and chronic constipation. *J Clin Gastroenterol*. 2012;46(9):748-751. <https://www.ncbi.nlm.nih.gov/pubmed/22810107>


Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. *Eur J Gastroenterol Hepatol*. 2010;22:1402-1411. <https://www.ncbi.nlm.nih.gov/pubmed/21389791>

Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. *Am J Gastroenterol*. 2016; 111(12):1824-1832. <https://www.nature.com/articles/ajg2016434>

Ford AC, Moayyedi P, Lacy BE, Lembo AJ, et al; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol*. 2014;109(Suppl 1):S2-26; quiz S27. <https://www.ncbi.nlm.nih.gov/pubmed/25091148>

Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA. Molecular characterization of eluxadolone as a potential ligand targeting mu-delta opioid receptor heteromers. *Biochem Pharmacol*. 2014;92(3): 448-456. <https://www.sciencedirect.com/science/article/pii/S0006295214005590?via%3Dihub>

Halpert A. Irritable Bowel Syndrome: Patient-Provider Interaction and Patient Education. *J Clin Med*. 2018;7(1):3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791011/>



IBS-D: What to Do When Typical Treatment Methods Fail

Darren M. Brenner, MD, AGAF

REFERENCES (cont'd)

Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clin Gastroenterol*. 2014;48(6):505-512. <https://www.ncbi.nlm.nih.gov/pubmed/24100754>

Lackner JM, Jaccard J, Keefer L, et al. Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. *Gastroenterology*. 2018;155(1):47-57. <https://www.ncbi.nlm.nih.gov/pubmed/29702118>

Lacy BE, Mearin F, Chang L, et al. Bowel disorders. *Gastroenterology*. 2016;150(6):1393-1407.e5. [https://www.gastrojournal.org/article/S0016-5085\(16\)00222-5/abstract](https://www.gastrojournal.org/article/S0016-5085(16)00222-5/abstract)

Lembo A, Pimentel M, Rao SS, et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. *Gastroenterology*. 2016;151(6):1113-1121. <https://www.ncbi.nlm.nih.gov/pubmed/27528177>

Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. *Dig Dis Sci*. 2010;55(9):2441-2449. <https://www.ncbi.nlm.nih.gov/pubmed/20467896>

Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. *J Am Diet Assoc*. 2006;106(10):1631-1639. <https://www.ncbi.nlm.nih.gov/pubmed/17000196>

Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. *Clin Gastroenterol Hepatol*. 2008;6(7):765-771. [https://www.cghjournal.org/article/S1542-3565\(08\)00151-1/fulltext](https://www.cghjournal.org/article/S1542-3565(08)00151-1/fulltext)

Spencer M, Chey WD, Eswaran S. Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy? *Curr Treat Options Gastroenterol*. 2014;12(4):424-440. <https://www.ncbi.nlm.nih.gov/pubmed/25219357>

Stacey D, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2014 Jan 28;(1):CD001431. <https://www.ncbi.nlm.nih.gov/pubmed/24470076>

Wade OPR, Palmer JM, McKenney S, Kenigs V, et al. Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/ μ opioid receptor antagonist. *Br J Pharmacol*. 2012;167(5):1111-1125. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492991/>

Wong BS, Camilleri M, Carlson P, et al. Increased Bile Acid Biosynthesis Is Associated With Irritable Bowel Syndrome With Diarrhea. *Clin Gastroenterol Hepatol*. 2012;10(9):1009-1115.e3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565429/>